News & Events
News & Events
[2019 Pasteur Colloquium] Tatsuo Ido, Ph.D., Neuroscience Research Institute, Gachon University
2019-08-23
______________________________________
IPK Pasteur Colloquium
Date : Wed. Aug. 28, 2019 at 11:00am
Venue : Monod Room (1F), Institut Pasteur Korea
___________________________________________________________________________________________
SPEAKER
Tatsuo Ido, Ph.D.
Chair Professor & Director of Theragnostic Compound R&D Center, Neuroscience Research Institute, Gachon University
TALK TITLE
Development of PET radiopharmaceuticals and its application to Boron Neutron Capture Therapy
* For more information, please contact at sukyon.yang@ip-korea.org or visit our website: www.ip-korea.org.
** Directions to IPK: http://www.ip-korea.org/about_us/location.php
IPK Pasteur Colloquium
Date : Wed. Aug. 28, 2019 at 11:00am
Venue : Monod Room (1F), Institut Pasteur Korea
___________________________________________________________________________________________
SPEAKER
Tatsuo Ido, Ph.D.
Chair Professor & Director of Theragnostic Compound R&D Center, Neuroscience Research Institute, Gachon University
TALK TITLE
Development of PET radiopharmaceuticals and its application to Boron Neutron Capture Therapy
ABSTRACT
PET (Positron Emission Tomography) is one of the most effective methodologies for the functional and molecular imaging with high sensitivity and high quantitative measurement. This consists from the coincident matrix detection technique and the in-vivo positron tracer.
PET (Positron Emission Tomography) is one of the most effective methodologies for the functional and molecular imaging with high sensitivity and high quantitative measurement. This consists from the coincident matrix detection technique and the in-vivo positron tracer.
In 1976, first brain regional glucose consumption mapping in human had been succeeded with 18FDG in collaboration among of BNL NIH and Pen-Univ. These regional glucose consumption mapping had led to understanding of the function of central nerves system (specially, sensor cortex and motor cortex). 18FDG is also widely used for PET diagnosis of various tumor based on the tracer study of energy metabolism.
In 1982, the first neuro-receptor imaging (Dopamine D2) of human brain in-vivo with 11C-methylspiperon was succeeded in the collaborative work between Johns Hopkins Medical School and Uppsala University. This was the starting point of the molecular imaging by PET. After this, the compounds rerated to signal transduction (agonist, antagonist) were labelled with 11C or 18F and applied to determine synapse activity.
Recent highlight works in Brain PET research are the imaging of amyloidal plaque and active tau protein for Alzheimer Disease patient. 11C- and 18F-labelled thioflavin analogs have been developed as amyloidal plaque marker. Active tau protein image by 18F-THK compound (quinoline derivative) is closer related to cell denature than the amyloidal plaque image.
Another highlight work is the imaging of neuro-inflammation that may be important to find tissue denature at early stages in Parkinson Diseases, Alzheimer Disease and other neurodegenerative diseases. For this purpose, TSPO (translocator protein) ligand (phenoxyphenyl acetamide and oxo-purine derivatives) is labelled with 11C and 18F.
Also challenging application of PET to BNCT(cancer treatment) is progress to estimate the boron(10B) concentration in the target tumor.
______________________________________
In 1982, the first neuro-receptor imaging (Dopamine D2) of human brain in-vivo with 11C-methylspiperon was succeeded in the collaborative work between Johns Hopkins Medical School and Uppsala University. This was the starting point of the molecular imaging by PET. After this, the compounds rerated to signal transduction (agonist, antagonist) were labelled with 11C or 18F and applied to determine synapse activity.
Recent highlight works in Brain PET research are the imaging of amyloidal plaque and active tau protein for Alzheimer Disease patient. 11C- and 18F-labelled thioflavin analogs have been developed as amyloidal plaque marker. Active tau protein image by 18F-THK compound (quinoline derivative) is closer related to cell denature than the amyloidal plaque image.
Another highlight work is the imaging of neuro-inflammation that may be important to find tissue denature at early stages in Parkinson Diseases, Alzheimer Disease and other neurodegenerative diseases. For this purpose, TSPO (translocator protein) ligand (phenoxyphenyl acetamide and oxo-purine derivatives) is labelled with 11C and 18F.
Also challenging application of PET to BNCT(cancer treatment) is progress to estimate the boron(10B) concentration in the target tumor.
______________________________________
* For more information, please contact at sukyon.yang@ip-korea.org or visit our website: www.ip-korea.org.
** Directions to IPK: http://www.ip-korea.org/about_us/location.php